Bristol Myers Squibb's High-Yield Dividend Faces a Risky Future
💡 Key Takeaway
Despite a tempting 4.4% yield, Bristol Myers Squibb's dividend is under threat from upcoming patent expirations on its top-selling drugs, making it a risky income investment.
The Allure and the Alarm Bells
Bristol Myers Squibb (BMY) is a major pharmaceutical company currently offering a dividend yield of 4.4%, which is significantly higher than the S&P 500 average. The company has raised its dividend for 17 consecutive years and maintains a seemingly manageable payout ratio of 72%, making it appear like a classic, stable income stock.
However, the article highlights a critical flaw in focusing solely on this track record: past performance does not guarantee future payouts. The company is facing significant business headwinds that could jeopardize its financial stability.
The core issue is a series of looming patent cliffs. Key blockbuster drugs, including the blood thinner Eliquis and cancer treatment Opdivo, will lose patent protection in the coming years. This opens the door to generic competition, which typically erodes sales and profits dramatically.
This pressure is already visible in the company's financial outlook. After generating flat revenue of $48.2 billion last year, Bristol Myers is forecasting a decline to a range of $46 billion to $47.5 billion for the current year. This trend suggests the challenges are imminent, not distant.
Why Dividend Investors Should Be Cautious
For income-focused investors, the sustainability of the dividend is paramount. A company needs strong, predictable cash flow to maintain and grow its shareholder payments. The patent cliffs threatening BMY's revenue directly undermine that foundation.
As generic competition intensifies, the company's earnings and free cash flow are expected to decline. This puts the dividend at risk because there will be less money available to fund it. A high payout ratio during a period of falling profits becomes much more dangerous.
To counter these headwinds, Bristol Myers may be compelled to pursue expensive acquisitions to replenish its drug pipeline. Such moves often require taking on debt or spending cash reserves, further straining the balance sheet and the capital available for dividends.
Ultimately, the article argues that a good dividend stock should be a 'buy-and-forget' investment that provides reliable income without constant worry. Given the substantial uncertainty around BMY's core business over the next few years, it fails this test, as the possibility of a dividend cut or suspension is real.
Bobby Insight
Avoid Bristol Myers Squibb for its dividend; the business risk is too high for reliable income.
While the 4.4% yield is attractive, the looming patent cliffs on Eliquis and Opdivo create an unacceptable level of uncertainty for dividend sustainability. The company's forecast for declining revenue confirms these are near-term, not hypothetical, risks.
What This Means for Me
